CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.20204483

Available online at: http://www.iajps.com Review Article

NANOPARTICULATE DRUG DELIVERY SYSTEMS IN CYSTIC FIBROSIS THERAPY: A COMPREHENSIVE REVIEW OF FORMULATION STRATEGIES, MUCUS PENETRATION MECHANISMS, TARGETED PULMONARY DELIVERY, AND TRANSLATIONAL CHALLENGES

Pooja Pandurang Durke[1*], Prof. Dr. R. S. Wanare[2]

[1*, 2]Sudhakarrao Naik Institute of Pharmacy, Pusad, Yavatmal, Maharashtra-445204 India.

Abstract:

Nanoparticulate drug delivery systems have emerged as a transformative approach in the management of Cystic Fibrosis, a complex genetic disorder characterized by impaired mucociliary clearance, thickened airway mucus, and chronic pulmonary infections. Conventional therapeutic strategies, including antibiotics, mucolytics, and CFTR modulators, are often limited by poor mucus penetration, systemic side effects, and inadequate drug retention at the site of action. This comprehensive review highlights the potential of nanoparticulate systems to overcome these limitations through advanced formulation strategies, enhanced mucus penetration mechanisms, and targeted pulmonary delivery. The review systematically discusses various nanoparticulate carriers such as polymeric nanoparticles, liposomes, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, and nanoemulsions, emphasizing their design principles and functional advantages. Special attention is given to formulation strategies, including material selection, preparation techniques, surface modification, and drug loading approaches, which collectively influence therapeutic performance. The mechanisms governing mucus penetration, including particle size optimization, surface hydrophilicity, and PEGylation, are critically analyzed in the context of the unique pathophysiological environment of cystic fibrosis. Furthermore, the review explores targeted pulmonary delivery systems and inhalation devices that facilitate efficient drug deposition in the respiratory tract. Emerging therapeutic applications, including antibiotic delivery, gene therapy, RNA-based therapeutics, and genome editing technologies such as CRISPR-Cas9, are comprehensively evaluated. In vitro and in vivo evaluation models used to assess nanoparticle performance, safety, and efficacy are also discussed. Finally, key translational challenges, including scalability, regulatory considerations, and clinical applicability, are addressed, along with future perspectives for advancing nanomedicine in cystic fibrosis therapy. Overall, nanoparticulate systems represent a promising and versatile platform for improving therapeutic outcomes and quality of life in patients with cystic fibrosis.

Keywords:*Cystic fibrosis; Nanoparticulate drug delivery; Pulmonary delivery; Mucus penetration; Polymeric nanoparticles; Liposomes; Solid lipid nanoparticles; Nanostructured lipid carriers; Gene therapy; RNA therapeutics; CRISPR-Cas9; Inhalation systems; Biofilm targeting; Drug delivery systems*

Corresponding author:

Pooja Pandurang Durke,
Sudhakarrao Naik Institute of Pharmacy,
Pusad, Yavatmal, Maharashtra -445204 India.
Email ID: Poojadurke104@gmail.com

QR CODE

Please cite this article in press Pooja Pandurang Durke et al., Nanoparticulate Drug Delivery Systems In Cystic Fibrosis Therapy: A Comprehensive Review Of Formulation Strategies, Mucus Penetration Mechanisms, Targeted Pulmonary Delivery, And Translational Challenges., Indo Am. J. P. Sci, 2026; 13(05).,

INTRODUCTION:

Cystic Fibrosis

Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic disorder characterized by dysfunction of epithelial ion transport, leading to the production of thick, dehydrated, and viscous secretions. The disease primarily affects the respiratory, gastrointestinal, and reproductive systems, with pulmonary complications being the leading cause of morbidity and mortality. CF arises due to mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which functions as a chloride and bicarbonate channel. Impaired CFTR activity disrupts ionic balance and water transport across epithelial surfaces, resulting in the accumulation of dense mucus that obstructs airways and creates a favorable environment for persistent microbial colonization. Over time, this leads to progressive lung damage, reduced pulmonary function, and ultimately respiratory failure if not adequately managed.[1-5]



Figure 1: Normal Airway and Airway with cystic fibrosis

Epidemiology and Global Burden

Cystic fibrosis is one of the most common inherited disorders among Caucasian populations, with an estimated incidence of approximately 1 in 2,500 to 3,500 live births in Europe and North America. However, its prevalence is considerably lower in Asian populations, including India, where underdiagnosis and limited screening programs contribute to an unclear epidemiological picture. Globally, more than 100,000 individuals are estimated to be living with CF, with improved diagnostic techniques and therapeutic advancements significantly increasing life expectancy in developed countries. Despite these improvements, CF continues to impose a substantial healthcare burden due to frequent hospitalizations, chronic antibiotic use, and the need for lifelong multidisciplinary care. In low- and middle-income countries, delayed diagnosis, limited access to advanced therapies, and inadequate healthcare infrastructure further exacerbate disease outcomes.[6-12]

Pathophysiology: CFTR Mutation, Thick Mucus, and Chronic Infections

The hallmark of CF pathophysiology lies in mutations of the CFTR gene, most commonly the ΔF508 mutation, which leads to defective protein folding, impaired trafficking, and reduced channel function at the epithelial surface. The loss of functional CFTR results in decreased chloride secretion and increased sodium absorption, causing dehydration of the airway surface liquid. This dehydration leads to the formation of thick, sticky mucus that is difficult to clear through normal mucociliary mechanisms.[13-15]

The altered mucus environment facilitates the colonization of opportunistic pathogens, particularly *Pseudomonas aeruginosa*, which forms resilient biofilms that are highly resistant to antibiotics and host immune responses. Chronic infection triggers a persistent inflammatory response dominated by neutrophils, resulting in the release of proteases and reactive oxygen species that further damage lung tissue. This cycle of mucus obstruction, infection, and inflammation progressively deteriorates pulmonary function, making effective drug delivery to the site of action extremely challenging.

Limitations of Conventional Therapies

Current therapeutic strategies for CF primarily include antibiotics to control infections, mucolytics (such as dornase alfa) to reduce mucus viscosity, bronchodilators, anti-inflammatory agents, and CFTR modulators designed to restore protein function. While these treatments have significantly improved patient outcomes, they are associated with several limitations.

Antibiotic therapy often requires high and repeated dosing due to poor penetration into thick mucus and bacterial biofilms, leading to systemic toxicity and the emergence of multidrug-resistant strains. Mucolytic agents provide symptomatic relief but do not address the underlying defect in mucus production. CFTR modulators, although a major breakthrough, are effective only for specific mutation classes and remain prohibitively expensive for widespread use, especially in developing countries. Furthermore, conventional drug delivery systems frequently fail to achieve adequate drug concentration at the target site due to rapid clearance, enzymatic degradation, and poor retention within the pulmonary environment.[16-22]

Rationale for Nanoparticulate Drug Delivery

Nanoparticulate drug delivery systems have emerged as a promising approach to overcome the

limitations of conventional therapies in CF management. These systems, typically ranging from 10 to 500 nm in size, can be engineered to enhance drug solubility, stability, and bioavailability while enabling controlled and sustained release profiles.

One of the key advantages of nanoparticles is their ability to penetrate the dense mucus barrier, particularly when designed with hydrophilic and neutrally charged surfaces such as polyethylene glycol (PEG) coatings. Additionally, nanoparticles can be tailored for targeted delivery to infected or inflamed lung tissues, thereby improving therapeutic efficacy and reducing systemic side effects. They also offer the potential to co-deliver multiple therapeutic agents, including antibiotics, anti-inflammatory drugs, and gene therapies, within a single platform.

Importantly, nanoparticulate systems can protect drugs from enzymatic degradation and enhance their retention time within the lungs, making them particularly suitable for inhalation-based delivery. These attributes position nanotechnology as a transformative strategy in CF therapy, with the potential to address both symptomatic management and the underlying causes of the disease.[23-25]

Table 1: Comparison of Conventional vs Nanoparticulate Drug Delivery in CF

Parameter	Conventional Systems	Nanoparticulate Systems
Mucus Penetration	Poor	Enhanced (PEGylation, small size)
Drug Stability	Limited	Improved
Targeted Delivery	Minimal	High (ligand-based targeting)
Dosing Frequency	High	Reduced (controlled release)
Side Effects	Higher systemic toxicity	Reduced
Biofilm Penetration	Limited	Improved

Nanoparticulate Drug Delivery Systems

Nanoparticulate drug delivery systems represent an advanced and versatile platform designed to improve the therapeutic performance of drugs, particularly in complex diseases such as Cystic Fibrosis. These systems typically range in size from 10 to 500 nm and are engineered to enhance drug solubility, stability, permeability, and site-specific delivery. In the context of cystic fibrosis, nanoparticulate carriers are especially advantageous due to their ability to navigate the dense, viscoelastic mucus barrier and deliver therapeutic agents directly to the site of infection and inflammation within the lungs. Based on their composition and structural characteristics, nanoparticulate systems can be broadly classified into polymeric nanoparticles, lipid-based carriers, vesicular systems, and colloidal dispersions.[26-28]





Figure 2: Classification and structural representation of major nanoparticulate drug delivery systems used in pulmonary therapy

Definition and Classification of Nanoparticulate Systems[29-37]

Nanoparticulate drug delivery systems are submicron-sized carriers that encapsulate, adsorb, or conjugate active pharmaceutical ingredients to improve their pharmacokinetic and pharmacodynamic profiles. These systems are rationally designed to overcome biological barriers, provide controlled drug release, and enable targeted delivery.

Polymeric nanoparticles are among the most widely studied systems and are typically prepared using biodegradable polymers such as PLGA, chitosan, and alginate. They exist as nanospheres or nanocapsules, where the drug is either uniformly dispersed or confined within a core-shell structure. Their high stability and tunable release properties make them suitable for sustained pulmonary delivery.

Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate both hydrophilic and lipophilic drugs. Due to their biocompatibility and structural similarity to biological membranes, liposomes are particularly effective for pulmonary delivery and have been extensively explored for antibiotic delivery in CF.

Solid lipid nanoparticles (SLNs) are composed of solid lipids stabilized by surfactants and offer advantages such as improved drug stability and controlled release. However, their crystalline structure may limit drug loading capacity.

Nanostructured lipid carriers (NLCs) represent a second-generation lipid system that incorporates both solid and liquid lipids, resulting in a less ordered matrix and higher drug loading efficiency. NLCs also exhibit improved stability and reduced drug expulsion during storage.

Dendrimers are highly branched, tree-like macromolecules with a well-defined architecture and multiple surface functional groups. These systems enable precise drug conjugation and targeted delivery, although concerns regarding toxicity and cost remain.

Nanoemulsions are thermodynamically or kinetically stable dispersions of oil and water stabilized by surfactants, with droplet sizes typically in the nanometer range. They enhance the solubility and bioavailability of poorly water-soluble drugs and are suitable for inhalation-based delivery.

Advantages of Nanoparticulate Systems in Cystic Fibrosis

Nanoparticulate drug delivery systems offer several distinct advantages over conventional formulations, making them highly promising for cystic fibrosis therapy.

One of the most significant benefits is enhanced mucus penetration. The thick and sticky mucus in CF lungs acts as a formidable barrier to drug diffusion. Nanoparticles, particularly those with hydrophilic and neutrally charged surfaces (e.g., PEGylated systems), can diffuse through the mucus mesh more efficiently, ensuring improved drug access to infected epithelial cells.

Another key advantage is controlled and sustained drug release. Nanoparticles can be engineered to release drugs over an extended period, maintaining therapeutic concentrations in the lungs while reducing dosing frequency. This is particularly

beneficial in CF patients who require long-term and repeated treatments.

Nanoparticles also enable targeted drug delivery, either through passive targeting (via deposition in specific lung regions) or active targeting (via ligand-receptor interactions). This improves drug localization at the site of infection or inflammation, thereby enhancing therapeutic efficacy while minimizing systemic exposure.

Additionally, nanoparticulate systems contribute to reduced toxicity and side effects. By encapsulating drugs within a carrier system, nanoparticles can protect healthy tissues from exposure and reduce systemic absorption, which is especially important for potent antibiotics and anti-inflammatory agents used in CF management.

Table 2: Classification and Key Characteristics of Nanoparticulate Drug Delivery Systems

Type of Nanocarrier	Composition	Key Features	Limitations
Polymeric Nanoparticles	PLGA, chitosan	Controlled release, biodegradable	Complex preparation
Liposomes	Phospholipids	Biocompatible, dual drug loading	Stability issues
SLNs	Solid lipids	High stability, controlled release	Low drug loading
NLCs	Solid + liquid lipids	Improved loading, reduced expulsion	Formulation complexity
Dendrimers	Branched polymers	Precise targeting, high functionality	Toxicity concerns
Nanoemulsions	Oil-water systems	Enhanced solubility, easy preparation	Physical instability

Table 3: Advantages of Nanoparticulate Systems in Cystic Fibrosis Therapy

Advantage	Description	Impact in CF
Enhanced Penetration	Small size and surface modification	Improved mucus diffusion
Controlled Release	Sustained drug delivery	Reduced dosing frequency
Targeted Delivery	Ligand-based or passive targeting	Increased efficacy
Reduced Toxicity	Localized drug action	Lower systemic side effects

Overall, nanoparticulate drug delivery systems represent a transformative approach in the management of cystic fibrosis by addressing key challenges associated with mucus barriers, drug stability, and targeted pulmonary delivery. Their multifunctional capabilities position them as a critical component in the development of next-generation therapies aimed at improving patient outcomes and quality of life.

MUCUS PENETRATION MECHANISMS[38-49]

The airway mucus barrier represents one of the most critical challenges in pulmonary drug delivery, particularly in Cystic Fibrosis. In healthy individuals, mucus is a hydrated, viscoelastic gel that facilitates efficient mucociliary clearance. However, in cystic fibrosis, defective ion transport leads to dehydration of airway surface liquid, resulting in thickened, sticky mucus with altered rheological properties. This pathological mucus is enriched with mucins, extracellular DNA, actin filaments, and inflammatory debris, forming a dense and heterogeneous network that significantly restricts the diffusion of therapeutic agents. Consequently, understanding and overcoming mucus-associated barriers is essential for the successful design of nanoparticulate drug delivery systems.



Figure 3: Mechanisms of nanoparticle interaction with cystic fibrosis mucus—illustrating mucus mesh structure, biofilm presence, and diffusion versus entrapment behavior

Structure and Properties of CF Mucus

Cystic fibrosis mucus exhibits a highly entangled polymeric network primarily composed of mucin glycoproteins (MUC5AC and MUC5B), which are responsible for its gel-like consistency. The mesh spacing or pore size within this network is typically estimated to range between 100 and 500 nm, although this can vary depending on disease severity and local conditions. In CF patients, the mucus becomes more compact due to dehydration, reducing pore size and increasing viscoelasticity.

Additionally, the presence of negatively charged components such as sialic acid residues and DNA contributes to strong electrostatic interactions with positively charged drug carriers. This creates a significant barrier for conventional drug delivery systems, which are often trapped or rapidly cleared before reaching their target site. Furthermore, chronic infection leads to the formation of bacterial biofilms—particularly by *Pseudomonas aeruginosa*—which add an additional diffusion barrier and further complicate drug delivery.

Mucoadhesion vs Mucopenetration[50-53]

Nanoparticle interaction with mucus can be broadly categorized into two opposing mechanisms: mucoadhesion and mucopenetration.

Mucoadhesive nanoparticles are designed to interact strongly with mucus components through electrostatic, hydrogen bonding, or hydrophobic interactions. Polymers such as chitosan exhibit strong mucoadhesion due to their positive charge, which enhances retention time at the site of administration. While this can be beneficial for localized drug delivery, excessive adhesion may limit deep penetration into the mucus layer and restrict drug distribution.

In contrast, mucopenetrating nanoparticles are engineered to minimize interactions with mucus, allowing them to diffuse rapidly through the mucus mesh. These systems typically possess hydrophilic, neutrally charged surfaces that reduce binding to mucin fibers. Mucopenetrating particles are particularly advantageous in cystic fibrosis, where deep penetration into the mucus is necessary to reach infected epithelial cells and bacterial colonies embedded within biofilms.

Factors Influencing Mucus Penetration

The efficiency of nanoparticle diffusion through mucus is governed by several physicochemical parameters:

- **Particle Size:** Nanoparticles smaller than the mucus mesh pore size (generally <200 nm) exhibit enhanced diffusion. Larger particles are more likely to be sterically hindered and trapped within the mucus network.
- **Surface Charge:** Neutral or slightly negative nanoparticles demonstrate improved mobility, whereas positively charged particles tend to bind strongly to negatively charged mucins and become immobilized.
- **Hydrophilicity:** Hydrophilic surfaces reduce hydrophobic interactions with mucus components, facilitating smoother diffusion.
- **Surface Coating:** The presence of hydrophilic polymers such as polyethylene glycol (PEG) creates a steric barrier that prevents adhesion to mucus fibers.

Strategies to Enhance Mucus Penetration

To overcome mucus-related barriers, several advanced formulation strategies have been developed:

PEGylation and hydrophilic coatings are among the most effective approaches for producing mucus-inert nanoparticles. The dense coating of PEG chains reduces adhesive interactions and allows particles to move freely through the mucus network.

Enzyme-functionalized nanoparticles incorporate enzymes such as DNase or proteases that degrade mucus components, thereby reducing viscosity and enhancing drug diffusion. This strategy is particularly useful in CF, where extracellular DNA significantly contributes to mucus thickness.

Biofilm disruption strategies involve the use of nanoparticles capable of penetrating or disrupting bacterial biofilms. These systems may carry agents that interfere with biofilm integrity or enhance antibiotic penetration, thereby improving therapeutic outcomes.

Surface charge tuning is another important approach, where nanoparticles are engineered to possess near-neutral charge to balance penetration and retention. This helps avoid entrapment while maintaining sufficient interaction with target cells.

Interaction with Bacterial Biofilms

In cystic fibrosis, chronic infections are often associated with biofilm formation, particularly by *Pseudomonas aeruginosa*. Biofilms are structured communities of bacteria embedded in a self-produced extracellular polymeric matrix that acts as a protective barrier against antibiotics and immune responses.

Nanoparticles offer a unique advantage in overcoming biofilm-associated resistance. Due to their small size and modifiable surface properties, they can penetrate biofilm matrices more effectively than free drugs. Additionally, nanoparticles can be engineered to deliver high local concentrations of antibiotics or incorporate biofilm-disrupting agents, thereby enhancing bacterial eradication.

Table 4: Strategies for Enhancing Mucus Penetration

Strategy	Mechanism	Benefit in CF
PEGylation	Reduces adhesion	Improved diffusion
Enzyme Functionalization	Degrades mucus components	Reduced viscosity
Biofilm Targeting	Disrupts bacterial matrix	Enhanced antibiotic action
Charge Modification	Minimizes electrostatic binding	Better mobility

In conclusion, mucus penetration is a decisive factor in the success of nanoparticulate drug delivery systems for cystic fibrosis therapy. By optimizing particle size, surface properties, and functionalization strategies, it is possible to design nanoparticles capable of effectively navigating the dense mucus barrier and delivering drugs to their intended targets. This section forms a critical foundation for understanding how advanced nanocarriers can overcome one of the most significant obstacles in pulmonary drug delivery.

TARGETED PULMONARY DELIVERY[54-60]

Targeted pulmonary delivery represents a cornerstone in the effective management of Cystic Fibrosis, as it enables direct administration of therapeutic agents to the site of infection and inflammation within the lungs. This approach minimizes systemic exposure while maximizing local drug concentration, thereby improving therapeutic efficacy and reducing adverse effects. However, successful pulmonary targeting requires careful consideration of aerosol dynamics, particle engineering, deposition mechanisms, and inhalation device performance. Nanoparticulate systems, when appropriately designed, can be incorporated into inhalable formulations to overcome physiological barriers and achieve efficient drug delivery.



Figure 4: Pulmonary deposition of inhaled particles and devices used for targeted delivery in respiratory diseases

Principles of Pulmonary Drug Deposition

The deposition of inhaled particles within the respiratory tract is governed by aerodynamic behavior and airflow patterns. Three primary mechanisms influence particle deposition:

- **Inertial impaction**, which dominates in the upper airways and affects larger particles (>5 µm), causing them to deposit in the oropharyngeal region.
- **Gravitational sedimentation**, which is significant for particles in the range of 1–5 µm and facilitates deposition in the bronchi and bronchioles.
- **Brownian diffusion**, which governs the movement of very small particles (<1 µm), enabling them to reach the alveolar region.

For optimal pulmonary delivery, particles are generally engineered within an aerodynamic diameter range of 1–5 µm. Nanoparticles themselves are often incorporated into microparticles or aerosol droplets to achieve this optimal size range while retaining their nanoscale advantages upon deposition.

Deposition Models in the Lung

Understanding lung deposition patterns is essential for designing effective inhalable nanoparticle

systems. The respiratory tract can be broadly divided into three regions:

- **Conducting airways (trachea and bronchi):** Larger particles tend to deposit here due to inertial impaction.
- **Bronchioles:** Intermediate-sized particles deposit via sedimentation.
- **Alveolar region:** Fine particles and nanoparticle-loaded aerosols can penetrate deeply and deposit via diffusion.

In cystic fibrosis, altered airway geometry, mucus accumulation, and impaired airflow significantly affect deposition patterns. Computational and experimental deposition models, including cascade impactors and lung simulators, are often used to predict aerosol behavior and optimize formulation parameters.

anoparticle-Based Pulmonary Targeting

Nanoparticles offer unique advantages in achieving targeted pulmonary delivery. Once deposited in the lungs, they can penetrate mucus layers and deliver drugs directly to epithelial cells or bacterial biofilms. Targeting strategies can be broadly categorized as:

- **Passive targeting**, where nanoparticles accumulate in specific lung regions based on size, density, and aerodynamic properties.
- **Active targeting**, which involves functionalization of nanoparticles with ligands that bind to receptors on lung epithelial cells, macrophages, or infected tissues.

Additionally, stimuli-responsive nanoparticles that release drugs in response to environmental triggers such as pH, enzymes, or oxidative stress are being explored to enhance site-specific delivery in CF

Inhalation Devices for Pulmonary Delivery

The choice of inhalation device plays a critical role in determining the efficiency of drug delivery. The most commonly used devices include:

Nebulizers convert liquid formulations into aerosols and are widely used in CF therapy, particularly for delivering antibiotics and mucolytics. They are suitable for patients of all age groups but may require longer administration times.

Dry Powder Inhalers (DPIs) deliver drugs in powder form and rely on the patient's inspiratory effort for aerosolization. They offer better stability and portability but may be less effective in patients with compromised lung function.

Metered Dose Inhalers (MDIs) use propellants to deliver a fixed dose of medication. While convenient and widely used, they require proper coordination between actuation and inhalation.

Nanoparticle-based formulations can be adapted for use in all these devices, either as suspensions (for nebulizers) or as dry powders (for DPIs), enabling flexible and patient-specific treatment approaches.

Factors Influencing Targeted Delivery[61-64]

Several formulation and physiological factors influence the success of targeted pulmonary delivery:

- Aerodynamic particle size (mass median aerodynamic diameter, MMAD)
- Particle density and shape
- Hygroscopicity and aggregation behavior
- Breathing pattern and lung physiology
- Device performance and patient compliance

Optimizing these factors is essential to ensure efficient deposition, retention, and drug release within the lungs.

Table 5: Comparison of Inhalation Devices for Nanoparticle Delivery

Device	Formulation Type	Advantages	Limitations
Nebulizer	Liquid	Suitable for all patients	Time-consuming
DPI	Dry powder	Portable, stable	Requires strong inhalation
MDI	Aerosol	Convenient dosing	Coordination required

In conclusion, targeted pulmonary delivery is a critical component of nanoparticulate drug delivery systems for cystic fibrosis therapy. By integrating optimized particle engineering with efficient inhalation devices and a thorough understanding of lung deposition mechanisms, it is possible to achieve precise and effective drug delivery. This approach not only enhances therapeutic outcomes but also reduces systemic exposure and improves patient compliance, making it a key focus area in the advancement of CF treatment strategies.

THERAPEUTIC APPLICATIONS IN CYSTIC FIBROSIS[65-72]

Nanoparticulate drug delivery systems have opened new avenues for the treatment of Cystic Fibrosis by enabling efficient delivery of diverse therapeutic agents directly to the lungs. These systems not only improve the pharmacokinetics of conventional drugs but also facilitate the clinical translation of advanced therapies such as gene editing and RNA-based interventions. Given the multifactorial nature of CF characterized by chronic infection, inflammation, and genetic defects a combination of therapeutic strategies is often required for effective disease management.

Antibiotic Delivery

Chronic pulmonary infections, particularly those caused by *Pseudomonas aeruginosa*, remain a major cause of morbidity and mortality in cystic fibrosis. Conventional antibiotic therapy is often limited by poor penetration into thick mucus and bacterial biofilms, necessitating high doses and prolonged treatment durations.

Nanoparticle-based antibiotic delivery systems offer significant advantages by enhancing drug penetration through mucus and biofilms, increasing local drug concentration, and reducing systemic toxicity. Liposomes, polymeric nanoparticles, and lipid-based carriers have been extensively studied for the delivery of antibiotics such as tobramycin, ciprofloxacin, and aztreonam. These systems can provide sustained drug release, thereby reducing dosing frequency and improving patient compliance. Additionally, nanoparticles can be engineered to co-deliver antibiotics with biofilm-disrupting agents, further enhancing therapeutic efficacy.



Figure 5: Nanoparticle-enabled therapeutic strategies in cystic fibrosis, including antibiotic delivery, gene therapy, RNA therapeutics, and genome editing

GENE THERAPY[73-117]

Gene therapy represents a promising approach for addressing the root cause of cystic fibrosis by correcting or replacing the defective CFTR gene. Nanoparticles serve as non-viral vectors for gene delivery, offering advantages such as reduced immunogenicity, improved safety, and the ability to carry large genetic payloads.

Polymeric nanoparticles, liposomes, and lipid nanoparticles (LNPs) have been explored for delivering plasmid DNA encoding functional CFTR protein to airway epithelial cells. These systems protect genetic material from degradation and facilitate cellular uptake. However, challenges such as low transfection efficiency and transient gene expression remain significant barriers to clinical translation.

RNA-Based Therapeutics

RNA-based therapies, including messenger RNA (mRNA) and small interfering RNA (siRNA), have emerged as powerful tools for modulating gene expression in cystic fibrosis.

- **mRNA therapy** involves delivering synthetic mRNA encoding the functional CFTR protein, enabling direct protein

production within target cells without the need for nuclear entry.

- **siRNA therapy** targets specific mRNA sequences to silence genes involved in inflammation or mucus overproduction.

Nanoparticles play a crucial role in RNA delivery by protecting these molecules from enzymatic degradation and facilitating their transport across biological barriers. Lipid nanoparticles, in particular, have shown great promise due to their high encapsulation efficiency and ability to promote endosomal escape. Despite these advancements, challenges such as delivery efficiency, stability, and repeated dosing need to be addressed.

CRISPR-Based Genome Editing

The advent of CRISPR-Cas9 technology has revolutionized the field of gene therapy by enabling precise editing of disease-causing mutations. In cystic fibrosis, CRISPR-based approaches aim to correct CFTR gene mutations at the genomic level, offering the potential for a permanent cure.

Nanoparticles are being investigated as delivery vehicles for CRISPR components, including Cas9 protein and guide RNA. Compared to viral vectors, nanoparticle-based systems offer improved safety and reduced risk of insertional mutagenesis. However, efficient delivery to lung epithelial cells and avoidance of off-target effects remain critical challenges that must be overcome before clinical application.

Combination and Multimodal Therapies

Given the complex pathology of cystic fibrosis, combination therapies that address multiple aspects of the disease are gaining increasing attention. Nanoparticles can be engineered to co-deliver antibiotics, anti-inflammatory agents, and genetic material within a single platform, enabling synergistic therapeutic effects.

For instance, nanoparticles carrying both antibiotics and mucolytic agents can simultaneously reduce bacterial load and improve mucus clearance. Similarly, combining gene therapy with anti-inflammatory drugs may enhance overall treatment outcomes. Such multifunctional systems represent a promising direction for future CF therapy.

Table 6: Nanoparticle-Based Therapeutic Approaches in Cystic Fibrosis

Therapy Type	Mechanism	Nanocarrier Used	Advantages	Challenges
Antibiotics	Kill/inhibit bacteria	Liposomes, NPs	Enhanced penetration	Resistance
Gene Therapy	CFTR gene replacement	Polymeric NPs, LNPs	Targets root cause	Low efficiency
mRNA Therapy	Protein expression	Lipid NPs	No genome integration	Stability issues
siRNA Therapy	Gene silencing	Polymeric/lipid NPs	Target specificity	Delivery barriers
CRISPR	Gene editing	NPs	Permanent correction	Off-target effects

In summary, nanoparticulate systems have significantly expanded the therapeutic landscape of cystic fibrosis by enabling effective delivery of both conventional and advanced therapies. From improving antibiotic efficacy to facilitating gene editing, these systems offer a multifaceted approach to disease management. While substantial progress has been made, further research is required to overcome existing challenges and translate these innovations into clinically viable treatments.

***IN VITRO* AND *IN VIVO* EVALUATION[74-80]**

A systematic evaluation strategy is essential to validate the performance, safety, and translational potential of nanoparticulate systems intended for pulmonary delivery in Cystic Fibrosis. Due to the complex pathological environment of CF lungs, both in vitro and in vivo studies are required to comprehensively assess formulation behavior, mucus penetration, cellular interaction, and therapeutic efficacy.

***In Vitro* Evaluation**

In vitro evaluation plays a critical role in the initial screening and optimization of nanoparticulate formulations. These studies are designed to characterize physicochemical properties, drug release behavior, mucus penetration capability, and cellular interactions under controlled laboratory conditions.

The physicochemical characterization of nanoparticles includes parameters such as particle size, polydispersity index (PDI), and zeta potential, which are typically measured using dynamic light scattering techniques. These parameters are crucial in determining the stability of the formulation and its ability to penetrate the mucus barrier. Morphological analysis using transmission or scanning electron microscopy provides insights into particle shape and surface characteristics. Additionally, encapsulation efficiency and drug loading capacity are quantified to ensure adequate drug incorporation within the carrier system.

Drug release studies are conducted using dialysis membrane techniques or Franz diffusion cells to evaluate the release kinetics of the encapsulated drug. These studies help in understanding whether the formulation provides immediate or sustained release, which is particularly important for chronic conditions like cystic fibrosis. Mathematical modeling of release data further aids in elucidating the mechanism of drug release.

Mucus penetration studies are especially important in CF research due to the presence of thick and viscous mucus. These studies are performed using artificial mucus models or patient-derived sputum samples. Techniques such as multiple particle tracking and diffusion studies are employed to assess the ability of nanoparticles to traverse the mucus barrier. Additionally, biofilm penetration assays using pathogens like *Pseudomonas aeruginosa* are conducted to evaluate antimicrobial effectiveness.

Cell-based studies are carried out using lung epithelial cell lines and advanced air–liquid interface (ALI) models that closely mimic the respiratory environment. These studies assess cellular uptake, intracellular trafficking, cytotoxicity, and inflammatory responses. Parameters such as transepithelial electrical resistance (TEER) are measured to evaluate the integrity of the epithelial barrier. Cytotoxicity assays such as MTT and LDH further ensure the biocompatibility of the formulation.



Figure 6: *In vitro* evaluation strategies for nanoparticulate drug delivery systems

***In Vivo* Evaluation**

In vivo evaluation is essential for confirming the therapeutic efficacy, biodistribution, pharmacokinetics, and safety of nanoparticulate systems in a physiological environment. These studies provide critical insights that cannot be obtained from in vitro experiments alone.

Animal models, particularly cystic fibrosis mouse models with CFTR mutations, are widely used to simulate the disease condition. Nanoparticles are administered via inhalation, intratracheal instillation, or nebulization to mimic clinical delivery routes. These models help in evaluating lung deposition, retention time, and systemic distribution of the drug.

Pharmacokinetic studies are conducted to determine drug concentration profiles in lung tissues and plasma over time. Biodistribution studies, often performed using fluorescent or radiolabeled nanoparticles, provide information on the localization of the formulation within different regions of the lungs and other organs.

Therapeutic efficacy is assessed by measuring parameters such as reduction in bacterial load, improvement in lung function, and decrease in inflammatory markers. In infection models, colony-forming unit (CFU) counts are used to quantify bacterial clearance, particularly for pathogens like *Pseudomonas aeruginosa*. Histopathological analysis of lung tissues is performed to evaluate structural changes, inflammation, and potential toxicity.

Safety assessment is a crucial component of in vivo studies. Acute and chronic toxicity studies are conducted to evaluate the effects of repeated dosing. Parameters such as oxidative stress markers, immune response, and tissue integrity are carefully monitored to ensure that the nanoparticulate system is safe for long-term use.

Table 7: *In Vitro* and *In Vivo* Evaluation Parameters

Evaluation Type	Parameters Assessed	Methods Used	Significance
In Vitro	Size, PDI, zeta potential	DLS	Stability, penetration
	Drug release	Dialysis/Franz cell	Release kinetics
	Mucus diffusion	MPT	Penetration ability
	Cytotoxicity	MTT/LDH	Safety
In Vivo	Biodistribution	Imaging techniques	Targeting efficiency
	Pharmacokinetics	Plasma/tissue analysis	Drug behavior
	Efficacy	CFU count, biomarkers	Therapeutic outcome
	Toxicity	Histopathology	Safety validation



Figure 7: *in vivo* evaluation strategies for nanoparticulate drug delivery systems

CONCLUSION:

Nanoparticulate drug delivery systems have demonstrated significant potential in addressing the multifaceted challenges associated with cystic fibrosis therapy. By enabling enhanced mucus penetration, controlled drug release, and targeted pulmonary delivery, these systems offer clear advantages over conventional treatment approaches. The ability to engineer nanoparticles with tailored physicochemical properties allows for improved drug stability, optimized pharmacokinetics, and reduced systemic toxicity, which are critical for long-term disease management. The integration of advanced formulation strategies with innovative surface modification techniques has further enhanced the functionality of nanoparticulate systems, enabling efficient navigation through the dense mucus barrier and improved interaction with target cells. Moreover, the application of nanotechnology in emerging therapeutic domains, including gene therapy, RNA-based interventions, and genome editing, highlights its potential to address the underlying genetic basis of cystic fibrosis rather than merely managing symptoms. Despite these promising advancements, several challenges remain, particularly in terms of large-scale manufacturing, regulatory approval, long-term safety, and clinical translation. Addressing these issues requires interdisciplinary collaboration, robust preclinical and clinical studies, and the development of standardized evaluation protocols. In conclusion, nanoparticulate drug delivery systems represent a highly promising and rapidly evolving field with the potential to revolutionize cystic fibrosis therapy. Continued research and innovation in this area are expected to bridge the gap between laboratory findings and clinical application, ultimately leading to more effective, personalized, and patient-friendly treatment strategies.

CONFLICTS OF INTERESTS:

All authors have declared no conflict of interest.

REFERENCES:

1. Momtazmanesh S, Moghaddam SS, Ghamari SH, Rad EM, Rezaei N, Shobeiri P, et al. Global burden of chronic respiratory diseases and risk factors, 1990–2019: An update from the Global Burden of Disease Study 2019. *eClinicalMedicine*. 2023;59:101936.
2. Nobel Prize Outreach AB. The Nobel Prize in Chemistry 1925—Presentation Speech

[Internet]. Available from: https://www.nobelprize.org/prizes/chemistry/1925/summary/
3. World Health Organization. Addressing the impact of nanotechnology on health [Internet]. Available from: https://www.who.int/europe/activities/addressing-the-impact-of-nanotechnology-on-health
4. US Food and Drug Administration. Nanotechnology guidance documents [Internet]. Available from: https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-guidance-documents
5. US Food and Drug Administration. Nanotechnology [Internet]. Available from: https://www.fda.gov/about-fda/nctr-research-focusareas/nanotechnology
6. Rasmussen K, Schoonjans R, Jantunen P, Rauscher H. European Union legislation addressing environment, health and safety aspects of nanomaterials. In: Environmental Nanopollutants: Sources, Occurrence, Analysis and Fate. London: Royal Society of Chemistry; 2022.
7. Chan HW, Chow S, Zhang X, Zhao Y, Tong HHY, Chow SF. Inhalable nanoparticle-based dry powder formulations for respiratory diseases: Challenges and strategies for translational research. *AAPS PharmSciTech*. 2023;24:98.
8. Joseph TM, Mahapatra DK, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M, et al. Nanoparticles: Taking a unique position in medicine. *Nanomaterials*. 2023;13:574.
9. Loo CY, Lee WH, Zhou QT. Recent advances in inhaled nanoformulations of vaccines and therapeutics targeting respiratory viral infections. *Pharm Res*. 2023;40:1015–1036.
10. Barthold S, Kunschke N, Murgia X, Loretz B, Carvalho-Wodarz CDS, Lehr CM. Overview of inhaled nanopharmaceuticals. *J Aerosol Med Pulm Drug Deliv*. 2023;36:144–151.
11. Peng S, Wang W, Zhang R, Wu C, Pan X, Huang Z. Nano-formulations for pulmonary delivery: Past, present, and future perspectives. *Pharmaceutics*. 2024;16:161.
12. Jin Z, Gao Q, Wu K, Ouyang J, Guo W, Liang XJ. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy. *Adv Drug Deliv Rev*. 2023;202:115111.
13. Hami Z. Advantages of nano-based drug delivery systems. *Ann Mil Health Sci Res*. 2021;19:e112274.
14. Forest V, Pourchez J. Nano-delivery to the lung—by inhalation or other routes and why nano when micro is largely sufficient? *Adv Drug Deliv Rev*. 2022;183:114173.
15. Pedersen S. Inhalers and nebulizers: Which to choose and why. *Respir Med*. 1996;90:69–77.
16. Dolovich M. New propellant-free technologies under investigation. *J Aerosol Med*. 1999;12(Suppl 1):S9–S17.
17. Newman SP, Morén F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler. *Eur Respir J*. 1989;2:247–252.
18. Hu SS, Yang ZX, Wang S, Wang LP, He QQ, Tang H, et al. Zwitterionic polydopamine modified nanoparticles to overcome mucus and epithelial barriers. *Chem Eng J*. 2022;428:132107.
19. Huckaby JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus. *Adv Drug Deliv Rev*. 2018;124:125–139.
20. Boyd AC, Guo SL, Huang LL, Kerem B, Oren YS, Walker AJ, et al. New approaches to genetic therapies for cystic fibrosis. *J Cyst Fibros*. 2020;19:S54–S59.
21. Maldonado I, Gallego I, Enriquez-Rodriguez L, Ibarra AI, Arbe A, Mashal M, et al. Non-viral gene delivery for cystic fibrosis using niocarbosomes. *Surf Interfaces*. 2025;68:106639.
22. Zhang MJ, Lu HY, Xie LK, Liu XL, Cun DM, Yang MS. Inhaled RNA drugs for lung diseases. *Adv Drug Deliv Rev*. 2023;203:115144.
23. Bai X, Chen QJ, Li FQ, Teng YL, Tang MP, Huang J, et al. Optimized inhaled LNP formulation for mRNA therapy. *Nat Commun*. 2024;15:6844.
24. Zhang KQ, Zhou Y, Wang GL, Zhu B, Zhao ZY, Kong X, et al. Pulmonary mRNA delivery systems. *Chin Chem Lett*. 2025;36:111887.
25. Davies JC, Polineni D, Boyd AC, Donaldson S, Gill DR, Griesenbach U, et al. Lentiviral gene therapy for cystic fibrosis. *Am J Respir Crit Care Med*. 2024;210:1398–1408.
26. Gill NA, Fung V, VanKeulen-Miller R, Narasipura EA, Fenton OS. Non-viral mRNA cystic fibrosis therapies. *Expert Opin Drug Deliv*. 2025.
27. Taccetti G, Terlizzi V, Campana S, Dolce D, Ravenni N, Fevola C, et al. Antibiotic treatment of lung infections in cystic fibrosis. *Eur J Pediatr*. 2024;184:82.
28. Zou Y, Liang CM, Tang ZQ, Huang YT, Liang CF, Chen LM, et al. Biofilm-responsive nano-antibiotics. *ACS Nano*. 2025;19:29702–29716.
29. Zhou Y, Huang JY, Wang GL, Zhai ZZ, Ahmed MU, Xia X, et al. Inhalable microparticles for biofilm-associated infections. *Sci Bull*. 2023;68:3225–3239.
30. Qin SG, Xiao W, Zhou CM, Pu QQ, Deng X, Lan LF, et al. *Pseudomonas aeruginosa*: Pathogenesis and resistance. *Signal Transduct Target Ther*. 2022;7:199.

31. Blanco-Cabra N, Alcàcer-Almansa J, Admella J, Arévalo-Jaimes BV, Torrents E. Nanomedicine against biofilm infections. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2024;16:e1944.
32. Al-Momani H, Albalawi H, Al Balawi D, Khleifat KM, Aolymat I, Hamed S, et al. Silver nanoparticles enhance antibiotic efficacy. *Int J Nanomedicine*. 2024;19:12461–12481.
33. Maset RG, Hapeshi A, Lapage J, Harrington N, Littler J, Perrier S, et al. Nanoparticle–antibiotic synergy in biofilms. *NPJ Biofilms Microbiomes*. 2023;9:36.
34. Mall MA, Burgel PR, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. *Nat Rev Dis Primers*. 2024;10:53.
35. Polgreen PM, Comellas AP. Clinical phenotypes of cystic fibrosis carriers. *Annu Rev Med*. 2022;73:563–574.
36. Grasemann H, Ratjen F. Cystic fibrosis. *N Engl J Med*. 2023;389:1693–1707.
37. Jia SJ, Taylor-Cousar JL. CFTR modulator therapies. *Annu Rev Med*. 2023;74:413–426.
38. Graeber SY, Mall MA. Future of cystic fibrosis treatment. *Lancet*. 2023;402:1185–1198.
39. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, et al. Nanoparticle penetration in CF sputum. *Biomaterials*. 2009;30:2591–2597.
40. Zhao J, Qin L, Song RX, Su J, Yuan Y, Zhang X, et al. Liposome surface charge and lung barriers. *Eur J Pharm Biopharm*. 2022;172:101–111.
41. Yoosefian M, Sabaghian H. Silver nanoparticle-based drug delivery systems in the fight against COVID-19: Enhancing efficacy, reducing toxicity and improving drug bioavailability. *J Drug Target*. 2024;32:794–806.
42. Li X, Anton N, Ta TMC, Zhao M, Messaddeq N, Vandamme TF. Microencapsulation of nanoemulsions: Novel Trojan particles for bioactive lipid molecule delivery. *Int J Nanomedicine*. 2011;6:1313–1325.
43. Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: A review. *Int J Mol Sci*. 2014;15:5852–5873.
44. Zachar O. Nanomedicine formulations for respiratory infections by inhalation delivery: COVID-19 and beyond. *Med Hypotheses*. 2022;159:110753.
45. Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. *Acc Chem Res*. 2022;55:2–12.
46. Yang J, Jia L, He Z, Wang Y. Recent advances in SN-38 drug delivery system. *Int J Pharm*. 2023;637:122886.
47. Eloy JO, Petrilli R, Lee RJ. Targeting of drug nanocarriers. In: Eloy JO, Abriata JP, Marchetti JM, editors. *Nanocarriers for Drug Delivery*. Cham: Springer; 2021. p. 107–126.
48. Kuehl PJ, Grimes MJ, Dubose D, Burke M, Revelli DA, Gigliotti AP, et al. Inhalation delivery of topotecan is superior to intravenous exposure. *Drug Deliv*. 2018;25:1127–1136.
49. Amore E, Ferraro M, Manca ML, Gjomarkaj M, Giammona G, Pace E, et al. Mucoadhesive solid lipid microparticles for corticosteroid delivery. *Nanomedicine*. 2017;12:2287–2302.
50. Sevinc A, Kalender ME, Altinbas M, Ozkan M, Dikilitas M, Camci C. Irinotecan as second-line monotherapy for lung cancer. *Asian Pac J Cancer Prev*. 2011;12:1055–1059.
51. Meng QF, Tai W, Tian M, Zhuang X, Pan Y, Lai J, et al. Inhalation delivery of dexamethasone nanoparticles attenuates cytokine storm. *Sci Adv*. 2023;9:eadg3277.
52. Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for nebulized mRNA delivery. *Nat Biomed Eng*. 2021;5:1059–1068.
53. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanospheres for pulmonary delivery. *J Control Release*. 2005;102:373–381.
54. Andrée L, Oude Egberink R, Dodemont J, Hassani Besheli N, Yang F, Brock R, et al. Gelatin nanoparticles for mRNA delivery. *Nanomaterials*. 2022;12:3423.
55. Tomoda K, Ohkoshi T, Hirota K, Sonavane GS, Nakajima T, Terada H, et al. Inhalable nanocomposite particles for lung cancer treatment. *Colloids Surf B Biointerfaces*. 2009;71:177–182.
56. Jaulin N, Appel M, Passirani C, Barratt G, Labarre D. Reduced macrophage uptake of modified nanoparticles. *J Drug Target*. 2000;8:165–172.
57. Vij N. Nano-based theranostics for chronic obstructive lung diseases. *Expert Opin Drug Deliv*. 2011;8:1105–1109.
58. Pirooznia N, Hasannia S, Lotfi AS, Ghanei M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles. *J Nanobiotechnol*. 2012;10:20.
59. Tseng CL, Wang TW, Dong GC, Wu SYH, Young TH, Shieh MJ, et al. Gelatin nanoparticles with EGF conjugation for lung targeting. *Biomaterials*. 2007;28:3996–4005.
60. Hashimoto T, Yuba E, Harada A, Kono K. Dendrimer-based nanohybrids for drug delivery. *J Mater Chem B*. 2020;8:2826–2833.
61. Homayoonfal M, Aminianfar A, Asemi Z, Yousefi B. Nanoparticles for delivery of quercetin in cancer therapy. *Curr Med Chem*. 2024;31:1107–1141.

62. Gulin-Sarfraz T, Jonasson S, Wigenstam E, von Haartman E, Bucht A, Rosenholm JM. Mesoporous silica nanoparticles for pulmonary delivery. *Pharmaceutics*. 2019;11:149.
63. Castillo RR, Vallet-Regí M. Mesoporous silica nanoparticles in bacterial infections. *Int J Nanomedicine*. 2021;16:4409–4430.
64. Ren L, Wang L, Rehberg M, Stoeger T, Zhang J, Chen S. Quantum dots in respiratory system applications. *Front Immunol*. 2021;12:795232.
65. Kaltbeitzel J, Wich PR. Protein-based nanoparticles for drug delivery. *Angew Chem Int Ed*. 2023;62:e202216097.
66. Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. *Pharmaceutics*. 2020;12:604.
67. Chen X, Li H, Ma Y, Jiang Y. Calcium phosphate nanomaterials in biomedical applications. *Molecules*. 2023;28:4790.
68. Hasanzadeh L, Kazemi Oskuee R, Sadri K, Nourmohammadi E, Mohajeri M, Mardani Z, et al. Biodistribution of labeled nanoparticles in mice. *Life Sci*. 2018;212:233–240.
69. Popowski KD, López de Juan Abad B, George A, Silkstone D, Belcher E, Chung J, et al. Inhalable exosomes outperform liposomes for lung delivery. *Extracell Vesicles*. 2022;1:100002.
70. Swetha K, Kotla NG, Tunki L, Jayaraj A, Bhargava SK, Hu H, et al. Lipid nanoparticle-mediated delivery of mRNA vaccines. *Vaccines*. 2023;11:658.
71. Kim J, Jozic A, Lin Y, Eygeris Y, Bloom E, Tan X, et al. Engineering lipid nanoparticles for inhalation delivery of mRNA. *ACS Nano*. 2022;16:14792–14806.
72. Dinakar YH, Karole A, Parvez S, Jain V, Mudavath SL. Stimuli-responsive nanocarriers for lung therapy. *Life Sci*. 2022;310:121133.
73. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–31.
74. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010.
75. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45–56.
76. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–70.
77. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, et al. A periciliary brush promotes the lung health. Science. 2012;337(6097):937–41.
78. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on nanoparticle characterization. Pharmaceutics. 2018;10(2):57.
79. Mohammadi M, Abedi A, Khorasani S. Nanoparticles in drug delivery systems. J Drug Deliv Sci Technol. 2018;44:1–7.
80. Ventola CL. The nanomedicine revolution: part 1. P T. 2017;42(12):742–55.
81. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine. Clin Pharmacol Ther. 2008;83(5):761–9.
82. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable carrier. Polymers. 2011;3(3):1377–97.
83. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug delivery. Adv Drug Deliv Rev. 2012;64:61–71.
84. Mehnert W, Mäder K. Solid lipid nanoparticles. Adv Drug Deliv Rev. 2012;64:83–101.
85. Müller RH, Radtke M, Wissing SA. Nanostructured lipid carriers. Adv Drug Deliv Rev. 2002;54:S131–55.
86. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances in liposomal drug delivery. Front Pharmacol. 2015;6:286.
87. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles. Adv Drug Deliv Rev. 2009;61(2):158–71.
88. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75–85.
89. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, et al. The penetration of mucus by nanoparticles. Biomaterials. 2009;30(13):2591–7.
90. Duncan GA, Jung J, Hanes J, Suk JS. The mucus barrier to inhaled gene therapy. Mol Ther. 2016;24(12):2043–53.
91. Peppas NA, Wood KM, Blanchette JO. Hydrogels for oral delivery. Eur J Pharm Biopharm. 2004;58:447–55.
92. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
93. Labiris NR, Dolovich MB. Pulmonary drug delivery. Br J Clin Pharmacol. 2003;56(6):588–99.
94. Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition. Int J Pharm. 2011;406(1–2):1–10.
95. Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. AAPS PharmSciTech. 2013;14(2):527–37.
96. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, et al. Ciprofloxacin nanoliposomes. Antimicrob Agents Chemother. 2008;52(7):2452–9.
97. Yang W, Peters JI, Williams RO. Inhaled nanoparticles. Int J Pharm. 2008;356(1–2):239–47.

98. d'Angelo I, Conte C, Miro A, Quaglia F, Ungaro F. Improving aerosol performance of nanoparticulate systems. Eur J Pharm Biopharm. 2016;109:123–34.
99. Griesenbach U, Alton EWFW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet. 2013;22(R1):R52–8.
100. Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, et al. Repeated nebulisation of non-viral CFTR gene therapy. Lancet Respir Med. 2015;3(9):684–91.
101. Robinson E, MacDonald KD, Slaughter K, McKinney M, Patel S, Sun C, et al. Lipid nanoparticle-delivered mRNA. Mol Ther. 2018;26(8):2036–46.
102. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: RNA therapeutics. Mol Ther. 2019;27(4):710–28.
103. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
104. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional repair of CFTR by CRISPR. Cell Stem Cell. 2013;13(6):653–8.
105. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene delivery. Nat Rev Genet. 2014;15(8):541–55.
106. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions. Science. 2010;328(5986):1662–8.
107. Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Caldwell CC, Matu JO. Biofilm formation in Pseudomonas infections. Trends Microbiol. 2009;17(1):27–34.
108. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of bioluminescence imaging. Biomaterials. 2010;31(3):628–36.
109. Kim H, Kim J, Lee YM. Advanced nanoparticle systems for pulmonary delivery. Pharmaceutics. 2020;12(6):567.
110. Choi YH, Han HK. Nanomedicines for respiratory diseases. J Control Release. 2018;240:510–25.
111. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299–319.
112. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size on drug delivery. Int J Pharm. 2010;383(1–2):221–9.
113. Zhao Y, Wang W, Guo S. Nanoparticle-based drug delivery in lung diseases. J Nanobiotechnol. 2021;19:234.
114. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems. J Nanobiotechnol. 2018;16:71.
115. Ahmad Z, Pandey R, Sharma S, Khuller GK. Liposome-based inhalable delivery. Drug Deliv. 2006;13(3):191–6.
116. Conte C, Ungaro F, Quaglia F. Polymer-based nanoparticles in CF. Adv Drug Deliv Rev. 2021;176:113857.
117. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation strategies for mucus penetration. Adv Drug Deliv Rev. 2016;99:28–51.